Our Research and Development Drive
We are strongly committed to innovative therapeutic research and development in Canada, and to realizing our vision of providing therapeutic Value Through Innovation.
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Areas of Expertise
The discovery of new drugs involves the evaluation and design of thousands of compounds to select a candidate with the desired levels of specificity, efficacy and safety. An understanding of the biochemical events associated with disease is necessary, along with the ability to identify and assess the novel chemical entities that influence these biochemical events.
Drug Discovery Support
The Drug Discovery Support (DDS) team works closely with a research team of biologists and medicinal chemists to provide critical information on new chemical entities. The team provides key information on the biopharmaceutical properties of new entities. This includes solubility, permeability and metabolic stability. DDS also carefully considers the safety of the chemicals and how they will be distributed to target sites.
The DDS group is truly multidisciplinary, consisting of specialists in pharmaceutics, pharmacology and pharmacokinetics (PK), including drug absorption, distribution, metabolism and excretion (ADME). Using state-of-the-art robotic stations and highly sensitive bioanalytical methods based on mass spectrometry, this group conducts highthroughput ADME-PK trials with high sensitivity and data accuracy. The research team is given integrated data analysis and interpretation which helps them understand the relationships between structural and biological properties of drug candidates. With such excellent interdisciplinary support, the researchers can then build models that will predict more accurately the biological properties of future compounds. The recently renovated pharmaceutics laboratory is equipped to perform X-ray powder diffraction, dissolution and stability studies and allows the DDS group to perform early solid-form characterization, salt form selection, and data-driven formulation design.